Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Nichi-Iko Pharmaceutical Co Ltd
Gross Profit
Nichi-Iko Pharmaceutical Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
Gross Profit
¥4B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Gross Profit
¥3T
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Gross Profit
¥1.3T
|
CAGR 3-Years
26%
|
CAGR 5-Years
18%
|
CAGR 10-Years
9%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Gross Profit
¥1.6T
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Gross Profit
¥805.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Gross Profit
¥1.4T
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
Nichi-Iko Pharmaceutical Co Ltd
Glance View
Nichi-Iko Pharmaceutical Co., Ltd., founded in Toyama, Japan, weaves its narrative around the essential fabric of healthcare by pioneering affordable and accessible medication. As a distinguished player in the generic pharmaceutical industry, Nichi-Iko specializes in the development, manufacture, and sale of a broad spectrum of generic drugs. Driven by the mission to enhance quality of life, the company meticulously focuses on producing high-quality, cost-effective alternatives to branded medications, thereby easing the financial burden on healthcare systems and patients alike. Its portfolio spans various therapeutic areas, strengthening its presence in both domestic and international markets. By investing strategically in R&D and leveraging advanced production techniques, Nichi-Iko ensures that its offerings meet rigorous standards, reinforcing trust and reliability in its brand. Financially, Nichi-Iko's revenue stream primarily hinges on the consistent demand for generics, amplified by the growing global emphasis on reducing healthcare costs. Licensing agreements and partnerships further bolster its financial framework, allowing the company to expand its product range and reach. The business model thrives on optimizing supply chain efficiencies and achieving economies of scale, translating into competitive pricing. Nichi-Iko’s commitment to innovation is not confined to generics; it is also venturing into biosimilars, tapping into a burgeoning market with expansive growth potential. By aligning its strategic direction with emerging healthcare trends and regulatory landscapes, Nichi-Iko positions itself as a resilient entity capable of sustaining its growth trajectory in a dynamic pharmaceutical sector.
See Also
What is Nichi-Iko Pharmaceutical Co Ltd's Gross Profit?
Gross Profit
4B
JPY
Based on the financial report for Mar 31, 2022, Nichi-Iko Pharmaceutical Co Ltd's Gross Profit amounts to 4B JPY.
What is Nichi-Iko Pharmaceutical Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
-36%
Over the last year, the Gross Profit growth was -81%. The average annual Gross Profit growth rates for Nichi-Iko Pharmaceutical Co Ltd have been -51% over the past three years , -36% over the past five years .
You don't have any saved screeners yet
